MOG antibody disease manifesting as progressive cognitive deterioration and behavioral changes with primary central nervous system vasculitis

Toshikazu Baba, Koji Shinoda, mitsuru watanabe, Shoko Sadashima, Dai Matsuse, Noriko Isobe, Ryo Yamasaki, Kimihiko Kaneko, Toshiyuki Takahashi, Toru Iwaki, Jun-Ichi Kira

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抄録

We report a 60-year-old male with anti-myelin oligodendrocyte glycoprotein (MOG) antibody who developed progressive cognitive deterioration and behavioral changes, with no other focal signs, over 9 months. MRI showed numerous T2-hyperintense lesions with partial contrast enhancement in white and grey matter of cerebrum, cerebellum and spinal cord. A brain biopsy revealed perivascular inflammatory cell infiltration, disturbed vascular continuity and no demyelination, indicative of a lymphocytic pattern of primary CNS vasculitis (PCNSV). Contrast enhancement disappeared after immunotherapy; however, cognitive impairment was not improved. Neurologists should note that MOG antibody disease can present as immunotherapy-resistant progressive cognitive impairment with PCNSV-like histopathology.

元の言語英語
ページ(範囲)48-50
ページ数3
ジャーナルMultiple Sclerosis and Related Disorders
30
DOI
出版物ステータス出版済み - 5 1 2019

Fingerprint

Myelin-Oligodendrocyte Glycoprotein
Central Nervous System Vasculitis
Immunotherapy
Antibodies
Cerebrum
Demyelinating Diseases
Cerebellum
Blood Vessels
Spinal Cord
Biopsy
Brain
Cognitive Dysfunction
Neurologists
White Matter
Gray Matter

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

これを引用

@article{6eff2a382252425a8ab51df5b17f463d,
title = "MOG antibody disease manifesting as progressive cognitive deterioration and behavioral changes with primary central nervous system vasculitis",
abstract = "We report a 60-year-old male with anti-myelin oligodendrocyte glycoprotein (MOG) antibody who developed progressive cognitive deterioration and behavioral changes, with no other focal signs, over 9 months. MRI showed numerous T2-hyperintense lesions with partial contrast enhancement in white and grey matter of cerebrum, cerebellum and spinal cord. A brain biopsy revealed perivascular inflammatory cell infiltration, disturbed vascular continuity and no demyelination, indicative of a lymphocytic pattern of primary CNS vasculitis (PCNSV). Contrast enhancement disappeared after immunotherapy; however, cognitive impairment was not improved. Neurologists should note that MOG antibody disease can present as immunotherapy-resistant progressive cognitive impairment with PCNSV-like histopathology.",
author = "Toshikazu Baba and Koji Shinoda and mitsuru watanabe and Shoko Sadashima and Dai Matsuse and Noriko Isobe and Ryo Yamasaki and Kimihiko Kaneko and Toshiyuki Takahashi and Toru Iwaki and Jun-Ichi Kira",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.msard.2019.01.053",
language = "English",
volume = "30",
pages = "48--50",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",

}

TY - JOUR

T1 - MOG antibody disease manifesting as progressive cognitive deterioration and behavioral changes with primary central nervous system vasculitis

AU - Baba, Toshikazu

AU - Shinoda, Koji

AU - watanabe, mitsuru

AU - Sadashima, Shoko

AU - Matsuse, Dai

AU - Isobe, Noriko

AU - Yamasaki, Ryo

AU - Kaneko, Kimihiko

AU - Takahashi, Toshiyuki

AU - Iwaki, Toru

AU - Kira, Jun-Ichi

PY - 2019/5/1

Y1 - 2019/5/1

N2 - We report a 60-year-old male with anti-myelin oligodendrocyte glycoprotein (MOG) antibody who developed progressive cognitive deterioration and behavioral changes, with no other focal signs, over 9 months. MRI showed numerous T2-hyperintense lesions with partial contrast enhancement in white and grey matter of cerebrum, cerebellum and spinal cord. A brain biopsy revealed perivascular inflammatory cell infiltration, disturbed vascular continuity and no demyelination, indicative of a lymphocytic pattern of primary CNS vasculitis (PCNSV). Contrast enhancement disappeared after immunotherapy; however, cognitive impairment was not improved. Neurologists should note that MOG antibody disease can present as immunotherapy-resistant progressive cognitive impairment with PCNSV-like histopathology.

AB - We report a 60-year-old male with anti-myelin oligodendrocyte glycoprotein (MOG) antibody who developed progressive cognitive deterioration and behavioral changes, with no other focal signs, over 9 months. MRI showed numerous T2-hyperintense lesions with partial contrast enhancement in white and grey matter of cerebrum, cerebellum and spinal cord. A brain biopsy revealed perivascular inflammatory cell infiltration, disturbed vascular continuity and no demyelination, indicative of a lymphocytic pattern of primary CNS vasculitis (PCNSV). Contrast enhancement disappeared after immunotherapy; however, cognitive impairment was not improved. Neurologists should note that MOG antibody disease can present as immunotherapy-resistant progressive cognitive impairment with PCNSV-like histopathology.

UR - http://www.scopus.com/inward/record.url?scp=85061051453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061051453&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2019.01.053

DO - 10.1016/j.msard.2019.01.053

M3 - Article

VL - 30

SP - 48

EP - 50

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

ER -